A detailed history of Royal Bank Of Canada transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Royal Bank Of Canada holds 12,918 shares of ADCT stock, worth $22,606. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,918
Previous 9,439 36.86%
Holding current value
$22,606
Previous $29,000 37.93%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.59 - $4.01 $9,010 - $13,950
3,479 Added 36.86%
12,918 $40,000
Q2 2024

Aug 14, 2024

BUY
$2.55 - $5.09 $16,342 - $32,621
6,409 Added 211.52%
9,439 $29,000
Q1 2024

Nov 05, 2024

SELL
$1.66 - $5.29 $10,638 - $33,903
-6,409 Reduced 67.9%
3,030 $13,000
Q1 2024

May 15, 2024

SELL
$1.66 - $5.29 $1,660 - $5,290
-1,000 Reduced 24.81%
3,030 $13,000
Q4 2023

Feb 14, 2024

SELL
$0.47 - $1.79 $1,905 - $7,258
-4,055 Reduced 50.15%
4,030 $6,000
Q3 2023

Nov 14, 2023

SELL
$0.72 - $2.37 $1,468 - $4,832
-2,039 Reduced 20.14%
8,085 $7,000
Q2 2023

Aug 14, 2023

BUY
$1.9 - $2.66 $5,929 - $8,301
3,121 Added 44.57%
10,124 $21,000
Q1 2023

May 15, 2023

BUY
$1.92 - $5.45 $2,636 - $7,482
1,373 Added 24.39%
7,003 $13,000
Q4 2022

Feb 14, 2023

BUY
$2.87 - $5.24 $10,443 - $19,068
3,639 Added 182.77%
5,630 $21,000
Q3 2022

Nov 14, 2022

BUY
$4.66 - $10.31 $2,330 - $5,155
500 Added 33.53%
1,991 $9,000
Q2 2022

Aug 15, 2022

BUY
$5.96 - $14.99 $3,576 - $8,994
600 Added 67.34%
1,491 $12,000
Q1 2022

May 16, 2022

BUY
$13.28 - $20.03 $5,471 - $8,252
412 Added 86.01%
891 $13,000
Q4 2021

Feb 14, 2022

SELL
$19.29 - $31.51 $7,677 - $12,540
-398 Reduced 45.38%
479 $10,000
Q3 2021

Nov 15, 2021

BUY
$20.45 - $30.0 $8,180 - $12,000
400 Added 83.86%
877 $24,000
Q2 2021

Aug 16, 2021

BUY
$20.38 - $27.04 $9,721 - $12,898
477 New
477 $12,000

Others Institutions Holding ADCT

About ADC Therapeutics SA


  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $136M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.